Old paths are such comforts. Losing them feels like losing the coziness of an old friendship. Today we took a new path through the woods and got a bit lost. The familiar markers were gone and their comfort and clarity gone with them. That’s often the way with forging a trail—you get easily disoriented. But …
Old paths are such comforts. Losing them feels like losing the coziness of an old friendship. Today we took a new path through the woods and got a bit lost. The familiar markers were gone and their comfort and clarity gone with them. That’s often the way with forging a trail—you get easily disoriented. But …
The OGF-OGFr axis, a novel biological pathway, can be modulated in human triple-negative breast cancer cells to inhibit proliferation, according to research in the June 2013 issue of Experimental Biology and Medicine. Exposure of human breast cancer cell lines to OGF in lab tests repressed growth within 24 hours. (That’s fast, folks.) Treatment with low dosages of the …
Triple-negative breast cancers may be vulnerable to drugs that attack the proteasome, a cellular structure that acts as the cell’s waste disposal, breaking down damaged or unneeded proteins, according to a new paper in Cancer Cell. In lab tests, researchers selectively “turned off” genes throughout the genomes of triple-negative tumor cells. When turned off, the cells die. These …
Scientists at the Genome Institute of Singapore (GIS) have identified genes that are potential targets for therapeutic drugs against triple-negative breast cancer. These findings were reported in the July 2013 issue of PNAS. In the research, they discovered that an enzyme, UBASH3B, was overexpressed in one third of TNBC patients. Deleting this gene expression inhibits TNBC growth and …